Zheng Quan Ri Bao Zhi Sheng·2026-01-06 13:09Core Viewpoint - The company, CanSino, has been deeply engaged in key areas such as meningitis vaccines, pneumonia vaccines, infant vaccines, innovative vaccination schemes, and adult vaccines for many years, and plans to continue enriching its pipeline through advanced technology platforms [1] Group 1: Current Focus Areas - The company is exploring innovative fields and expanding into areas such as tumor vaccines and therapeutic vaccines, aiming to develop differentiated competitive products [1] - mRNA technology is one of the company's leading platforms, recognized for its high platform value and broad development prospects [1] Group 2: Research and Development - The company has accumulated years of experience in the development and production of mRNA vaccines, including in-depth knowledge of infectious diseases and antigen screening [1] - In the therapeutic area, the company is advancing the development of mRNA vaccines for glioblastoma and rhabdomyosarcoma, aiming to expand the application range of its leading technology platform [1] Group 3: Technology and Licensing - The company has achieved external technology licensing for its proprietary new three-component lipid nanoparticle delivery system (ISL-3C-LNP) [1]